Equity Research

February 5, 2021 BSE Sensex: 50614

ICICI Securities Limited is the author and distributor of this report

Q3FY21 result review and estimate revision

Agriculture

Target price: Rs575

Earnings revision

FY21E	FY22E
↓ 10.0	↓ 10.0
↓ 7.5	↓ 5.0
↓ 8.2	↓ 5.5
	↓ 10.0 ↓ 7.5

Shareholding pattern

	Jun	Sep	Dec
	'20	'20	'20
Promoters	70.1	70.1	70.3
Institutional			
investors	5.8	17.3	5.4
MFs and others	1.9	2.0	2.2
Fls/Banks	0.4	0.0	0.0
FIIs	3.5	15.3	3.1
Others	24.1	12.6	24.4

Source: BSE



Research Analyst:

Aniruddha Joshi Aniruddha.joshi@icicisecurities.com +91 22 6637 7249

INDIA

PICICISecurities

Godrej Agrovet

ADD Maintained

Weak revenues but higher margins due to lower commodity prices

Rs532

Three pointers to note from Godrej Agrovet's Q3FY21: (1) There is still lower demand from HoReCa for milk, eggs and chicken. It impacted the company's Animal feed and Dairy segments, (2) Re-branding all dairy products under 'Godrej Jersey' brand will strengthen the dairy segment and will improve the ability to raise prices and maintain margins and (3) GAVL has continued to reduce investments in working capital which will lead to higher return ratios. Though Bird flu disease is expected to impact Poultry feed and Godrej Tyson for 1-2 quarters, we expect most segments of the company to show recovery in FY22 with favourable base of FY21. We remain confident of value creation (RoE > Cost of Equity) and maintain ADD with a DCF-based target price of Rs575 (25x FY23E).

- ▶ Q3FY21 result performance: Godrej Agrovet reported revenue decline of 14.4% and EBITDA and PAT growth of 11.7% and 21.2%, respectively. Animal feed, Oil Palm and Dairy segment revenues declined 22.7%, 16.6% and 10.1%, respectively due to localised lockdown, white fly attack, lower commodity prices and lower institutional sales. Astec reported revenue decline of 7.1% YoY.
- ▶ Deflation in input prices leads to higher gross margin: The company reported 540bps higher gross margin and EBITDA margin expanded 170bos YoY. The input prices for most segments were lower YoY. We believe cost savings measures initiated post covid have also helped to report better margins. The change in revenue mix (Higher share of Astec and palm oil and lower share of Animal Feed) also helped to improve the margins at consolidated level.
- ▶ Likely impact of Bird Flu: With Bird Flu disease impacting birds in multiple states in India, we believe the consumption of chicken and eggs to be impacted. We expect the impact to hurt the revenues of Poultry feed and Godrej Tyson for 1-2 quarters. We expect the situation to be back to normal by Q2FY22.
- ▶ Dairy business branded as 'Godrej Jersey': The company has re-launched all the dairy products under the brand 'Godrej Jersey'. We expect higher investments in the dairy business. We also believe Godrej brand equity will help to improve addressable market as well as improve the ability to raise prices and maintain margins. We expect benefits of this strategy in FY22-23.
- ▶ Maintain ADD: We expect GAVL to report revenue and PAT CAGRs of 4.9% and 12% respectively, over FY20-FY23E. The return ratios are also expected to be above cost of capital. We maintain ADD with a DCF based target price of Rs575 (25x FY23E). Key risks: Failure of new products and prolonged slow-down in out-of-home consumption.

Market Cap	Rs102bn/US\$1.4bn	Year to March	FY20	FY21E	FY22E	FY23E
Reuters/Bloomberg	GODE.BO/GOAGRO IN	Net Revenue (Rs mn)	69,640	63,752	71,593	80,424
Shares Outstanding	(mn) 192.1	Net Profit (Rs mn)	3,163	3,125	3,766	4,439
52-week Range (Rs)	580/280	Dil. EPS (Rs)	16.5	16.3	19.6	23.1
Free Float (%)	29.7	% Chg YoY	46.7	(1.2)	20.5	17.9
FII (%)	3.1	P/E (x)	32.3	32.7	27.1	23.0
Daily Volume (US\$'0	00) 1,283	CEPS (Rs)	24.2	24.5	28.8	33.0
Absolute Return 3m	(%) 1.4	EV/EBITDA (x)	23.3	19.4	16.8	14.9
Absolute Return 12m	(%) (7.1)	Dividend Yield (%)	1.0	1.0	1.1	1.3
Sensex Return 3m (%	%) 24.7	RoCE (%)	11.9	14.1	15.8	16.6
Sensex Return 12m ((%) 25.6	RoE (%)	16.5	16.4	17.8	18.5

Please refer to important disclosures at the end of this report

Table 1: Q3FY21 financial performance


(Rs mn, year ending March 31)

Y/e March	Q3FY21	Q3FY20	YoY gr. (%)	Q2FY21	QoQ gr. (%)
Revenue	15,262	17,827	(14.4)	17,239	(11.5)
Expenditure					
Raw materials	11,318	14,180	(20.2)	12,622	(10.3)
% of revenue	74.2	79.5		73.2	
Employee cost	994	924	7.6	987	0.7
% of revenue	6.5	5.2		5.7	
Other expenditure	1,825	1,717	6.3	1,899	(3.9)
% of revenue	12.0	9.6		11.0	
Total expenditure	14,137	16,821	(16.0)	15,508	(8.8)
EBITDA	1,124	1,006	11.7	1,732	(35.1)
EBITDA margin	7.4	5.6		10.0	
Other income	131	93	40.2	83	57.4
Profit from Associates	99	59	67.9	173	(42.7)
PBDIT	1,354	1,158	16.9	1,987	(31.9)
Depreciation	390.3	370.7	5.3	390.7	(0.1)
PBIT	964	788	22.4	1,597	(39.6)
Interest	63	108	(41.9)	96	(34.8)
PBT	901	680	32.6	1,501	(39.9)
Prov for tax	220	168	30.8	345	(36.2)
% of PBT	24.4	24.8		23.0	
Adjusted PAT	681	511	33.1	1,155	(41.1)
Extra ordinary items	(4)	(9)	(52.7)	4	(215.8)
Minority Interest	62	(5)	(1,393.8)	83	(25.5)
Reported PAT	614	507	21.2	1,076	(42.9)

Source: Company data, I-Sec research


Key performance highlights

Chart 1: Revenues and revenue growth



Source: Company data, I-Sec research

Chart 2: EBITDA margin



Source: Company data, I-Sec research

Segment-wise performance

Table 2: Segment-wise performance

(Rs mn)	Q3FY21	Q3FY20	YoY gr. (%)	Q2FY21	QoQ gr. (%)
Revenues					
Animal feed	7,833	10,130	(22.7)	7,623	2.7
Vegetable oil	1,878	2,250	(16.6)	2,932	(36.0)
Crop protection	2,209	2,180	1.3	3,328	(33.6)
Dairy	2,567	2,855	(10.1)	2,590	(0.9)
Others	1,615	1,652	(2.2)	1,574	2.6
Intersegment	(840)	(1,240)	(32.3)	(808)	3.9
Total	15,261	17,827	(14.4)	17,239	(11.5)
EBIT					
Animal feed	382	350	9.1	476	(19.8)
Vegetable oil	305	436	(30.0)	414	(26.3)
Crop protection	356	381	(6.5)	745	(52.2)
Dairy	68	(7)	(1,109.0)	41	64.1
Others	61	(176)	(134.5)	64	(5.7)
Intersegment	•	()	(10110)	0.	(0)
Total	1,172	984	19.0	1,742	(32.7)
	·			·	•
Revenues as % of Total					
Animal feed	51.3	56.8		44.2	
Vegetable oil	12.3	12.6		17.0	
Crop protection	14.5	12.2		19.3	
Dairy	16.8	16.0		15.0	
Others	10.6	9.3		9.1	
Intersegment	-5.5	-7.0		-4.7	
Total	100.0	100.0		100.0	
EBIT as % of Total					
Animal feed	32.6	35.6		27.4	
Vegetable oil	26.1	44.3		23.8	
Crop protection	30.4	38.7		42.8	
Dairy	5.8	-0.7		2.4	
Others	5.2	-17.9		3.7	
Intersegment	0.0	0.0		0.0	
Total	100.0	100.0		100.0	
EBIT margin (%)					
Animal feed	4.9	3.5		6.2	
Vegetable oil	16.3	19.4		14.1	
Crop protection	16.1	17.5		22.4	
Dairy	2.6	(0.2)		1.6	
Others	3.8	(10.7)		4.1	
Intersegment	-	-		-	
Total	7.7	5.5		10.1	

Source: Company data, I-Sec research

Key highlights from Q3FY21 results

- Animal feed segment reported volume decline of 16.5% YoY. Most of the hotels
 and restaurants are operating at lower capacity utilization. It is resulting in lower
 demand for cattle feed and poultry feed.
- Lower raw material prices have helped to improve margins of Animal Feed segment.
- White fly attack impacted the palm oil plantations and it resulted in lower arrival of fresh fruit bunches. Hence, Oil palm segment reported revenue decline of 16.6%. Lower yield as well as lower revenues resulted in EBIT decline of 30% YoY.
- Increase in palm oil prices by 33% helped company strong growth in Oil Palm segment in 9MFY21.
- The company is allotted an area of 28,164 hectares for palm oil development by Department of Horticulture, Telangana.
- The company introduced two herbicides during 9MFY21 as Delete Aqua and Impool-X.
- Astec reported 7.1% revenue growth due to deferment of orders and reduction in prices of one key product.
- Lower institutional and Out-of-home consumption of milk impacted revenues of Creamline Dairy. Revenues of Dairy segment declined 10.1% YoY. Correction is milk prices resulted in higher EBITDA margin.
- The company has re-launched entire dairy product range under the brand 'Godrej Jersey'.
- Lower sales of Live Birds and Godrej Real Good Chicken resulted in 1.8% lower revenues of Godrej Tyson Foods.
- Revenues of ACI Godrej Agrovet Bangladesh were up 25% YoY.
- Due to lower raw material prices for almost all segments, the gross margin expanded 540bps YoY. EBITDA margin was also up 170bps YoY.

Valuation and risks

We expect Godrej Agrovet (GAVL) to report revenue and PAT CAGRs of 4.9% and 12% over FY20-FY23E, respectively. We expect RoE to improve to 18.5% in FY23E from 16.5% in FY20. We value the stock on DCF basis with a target price of Rs575. At this target price, the implied P/E works out to 25x on FY23E EPS. We maintain ADD rating.

Table 3: DCF-based valuation

Particulars	Amt (Rs)
Cost of Equity (%)	10.8
Terminal growth rate (%)	4.0
Discounted interim cash flows (Rs mn)	35,144
Discounted terminal value (Rs mn)	75,272
Total equity value (Rs mn)	1,10,417
Value per share (Rs)	575

Source: Company data, I-Sec research

Risks

Lower than expected offtake of new products

Any failure of new products may impact our estimates.

Sharp increase in input prices and competition

Any major increase in commodity prices and/or competitive pressures will impact our earnings estimates.

Financial summary

Table 4: Profit & loss statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Net Sales	69,640	63,752	71,593	80,424
Operating Expenses	64,756	57,887	64,827	72,784
EBITDA	4,885	5,865	6,766	7,640
% margins	7.0	9.2	9.4	9.5
Depreciation & Amortisation	1,481	1,581	1,762	1,903
Gross Interest	416	604	532	532
Other Income	598	379	435	590
Recurring PBT	3,456	3,917	4,750	5,623
Less: Taxes	481	999	1,211	1,434
Less: Minority Interest	(59)	(64)	(71)	(78)
Net Income (Reported)	3,024	3,125	3,766	4,439
Extraordinaries (Net)	(139)	-	-	-
Recurring Net Income	3,163	3,125	3,766	4,439

Source: Company data, I-Sec research

Table 5: Balance sheet

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Assets				
Total Current Assets	20,746	20,934	23,522	26,822
of which cash & cash eqv.	508	351	714	1,514
Total Current Liabilities &				
Provisions	16,346	16,894	18,972	21,312
Net Current Assets	4,401	4,039	4,550	5,510
Investments	2,879	2,879	4,379	6,129
Net Fixed Assets	21,565	23,516	24,003	24,351
Capital Work-in-Progress	1,532	´ -	· -	· -
Total Assets	30,377	30,434	32,933	35,990
Liabilities				
Borrowings	8,449	6,649	6,649	6,649
Deferred Tax Liability	(278)	(278)	(278)	(278)
Minority Interest	3,825	3,825	3,825	3,825
Equity Share Capital	1,920	1,920	1,920	1,920
Face Value per share (Rs)	10	10	10	10
Reserves & Surplus*	16,461	18,318	20,817	23,874
Less: Misc. Exp. n.w.o.		· -	-	-
Net Worth	18,381	20,239	22,738	25,794
Total Liabilities	30,377	30,434	32,933	35,990

Source: Company data, I-Sec research

Table 6: Quarterly trend

(Rs mn, year ending March 31)

	Mar 20	June 20	Sept 20	Dec 20
Net sales	16,277	15,542	17,239	15,262
% growth (YoY)	21.1	(8.7)	(6.9)	(14.4)
EBITDA	1,263	1,659	1,732	1,124
Margin (%)	7.8	10.7	10.0	7.4
Other income	164	179	256	230
Extraordinaries (Net)	(126)	4	4	(4)
Adjusted Net profit	848	885	1,072	619

Source: Company data, I-Sec research

Table 7: Cashflow statement

(Rs mn, year ending March 31)

	FY20	FY21E	FY22E	FY23E
Operating Cashflow	4,123	4,706	5,528	6,342
Working Capital Changes	(2,204)	204	(148)	(160)
Capital Commitments	(2,575)	(2,000)	(2,250)	(2,250)
Free Cashflow	(657)	2,911	3,130	3,932
Cashflow from Investing				
Activities	(4)	-	(1,500)	(1,750)
Issue of Share Capital	2	-	-	-
Inc (Dec) in Borrowings	2,311	(1,800)	-	-
Dividend paid	(1,076)	(1,267)	(1,267)	(1,383)
Change in Deferred Tax				
Liability	(2,322)	-	-	-
Chg. in Cash & Bank				
balance	210	(157)	363	799
Caurage Company data I Ca	a raaaarah			

Source: Company data, I-Sec research

Table 8: Key ratios

(Year ending March 31)

(real ending March 31)	5 1/00	E)/0/E	E)/00E	E)/00E
	FY20	FY21E	FY22E	FY23E
Per Share Data (Rs)				
EPS	16.5	16.3	19.6	23.1
Cash EPS	24.2	24.5	28.8	33.0
Dividend per share (DPS)	5.5	5.5	6.0	7.0
Book Value per share (BV)	94.3	103.9	117.0	132.9
Growth (%)				
Net Sales	18.6	(8.5)	12.3	12.3
EBITDA	7.2	20.1	15.3	12.9
PAT	46.7	(1.2)	20.5	17.9
EPS	46.7	(1.2)	20.5	17.9
Valuation Ratios (x)				
P/E	32.3	32.7	27.1	23.0
P/CEPS	22.0	21.7	18.5	16.1
P/BV	5.6	5.1	4.5	4.0
EV / EBITDA	23.3	19.4	16.8	14.9
EV / Sales	1.6	1.8	1.6	1.4
Operating Ratios				
Raw Material / Sales (%)	77.2	75.0	74.8	74.7
Employee cost / Sales (%)	5.1	5.1	5.1	5.1
SG&A / Sales (%)	1.3	1.3	1.3	1.3
Other Income / PBT (%)	14	6	6	7
Effective Tax Rate (%)	14	26	26	26
Working Capital (days)	20.4	21.1	19.6	18.1
Inventory Turnover (days)	46.4	55.7	55.7	55.7
Receivables (days)	44.8	45.6	45.6	45.6
Payables (days)	67.5	76.7	76.7	76.7
Net D/E (x)	0.6	0.5	0.4	0.2
Profitability Ratios (%)				
Net Income Margins	4.3	4.6	4.9	5.2
RoACE	11.9	14.1	15.8	16.6
RoAE	16.5	16.4	17.8	18.5
Dividend Payout	33.4	33.8	30.6	30.3
Dividend Yield	1.0	1.0	1.1	1.3
EBITDA Margins	7.0	9.2	9.4	9.5
Courses Company data I Coo re	aaarah			

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Aniruddha Joshi, CA authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICIĆI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.